Antengene doses first patient in China in Phase III trial of ATG-022

Antengene Corp. said it has dosed the first patient in China in the pivotal Phase III CLINCH-3 trial of ATG-022 for CLDN18.2-positive advanced gastric cancers. The Phase III study will compare ATG-022 with investigator’s choice therapy.